OncoMatch/Clinical Trials/NCT05093231
Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer
Is NCT05093231 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Pembrolizumab and Olaparib for pancreatic cancer.
Treatment: Pembrolizumab · Olaparib — A phase II study combining pembrolizumab with olaparib in metastatic pancreatic adenocarcinoma patients with high tumour mutation burden
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage IV
Excluded: Stage RESECTABLE, III
Metastatic disease required
Radiologically confirmed stage 4 mPDA, with measurable disease; Patients with resectable or locally advanced PDA [excluded]
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immune checkpoint inhibitor
Prior immune checkpoint inhibitors or PARP inhibitors. This includes any prior therapy with an anti-PD-1, or anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g, CTLA-4, OX 40, CD137)
Cannot have received: PARP inhibitor
Prior immune checkpoint inhibitors or PARP inhibitors.
Cannot have received: systemic anti-cancer therapy
Exception: within 4 weeks prior to screening
Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to screening.
Cannot have received: radiotherapy
Exception: within 2 weeks of start of study intervention; 1-week washout permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease
Has received prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.
Lab requirements
Blood counts
ANC ≥1.5 x 10^9/L; Hb ≥ 90 g/L; platelets ≥100 x 10^9/L
Kidney function
creatinine clearance by Cockcroft-Gault ≥50 mL/min
Liver function
AST or ALT ≤2.5 x ULN, or <5 x ULN in the presence of liver metastases; total bilirubin <1.5 x ULN
Adequate bone marrow function: ANC ≥1.5 x 10^9/L, Hb ≥ 90 g/L, platelets ≥100 x 10^9/L; Adequate liver function: AST or ALT ≤2.5 x ULN, or <5 x ULN in the presence of liver metastases; total bilirubin <1.5 x ULN; Adequate renal function: creatinine clearance by Cockcroft-Gault ≥50 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify